drspdavid's profile picture. Radiation Oncologist at the Peter MacCallum Cancer Centre. Views are my own, healthy skeptic. #radonc

Steven David

@drspdavid

Radiation Oncologist at the Peter MacCallum Cancer Centre. Views are my own, healthy skeptic. #radonc

Pinned

🔬 AVATAR trial published(ER+/HER2– MBC on AI + CDK4/6i): In OPD, SABR delayed therapy change (mPFS 9.9 mo) 🔷 44% on same Rx at 12 mo 🔷 36% at 24 mo Some received SABR 2–3× for new oligoprogressions—modified endpoints may better reflect its value. ascopubs.org/doi/10.1200/OA…

drspdavid's tweet image. 🔬 AVATAR trial published(ER+/HER2– MBC on AI + CDK4/6i): In OPD, SABR delayed therapy change (mPFS 9.9 mo)
🔷 44% on same Rx at 12 mo
🔷 36% at 24 mo
Some received SABR 2–3× for new oligoprogressions—modified endpoints may better reflect its value. ascopubs.org/doi/10.1200/OA…
drspdavid's tweet image. 🔬 AVATAR trial published(ER+/HER2– MBC on AI + CDK4/6i): In OPD, SABR delayed therapy change (mPFS 9.9 mo)
🔷 44% on same Rx at 12 mo
🔷 36% at 24 mo
Some received SABR 2–3× for new oligoprogressions—modified endpoints may better reflect its value. ascopubs.org/doi/10.1200/OA…

Steven David reposted

Extraordinary case at #SABR2025 by @drspdavid and De Mark Shaw @PeterMacRadOnc oligoprogressive #breastcancer without switching drug therapy. 8 years of SABR with #radonc, with preserved quality of life from the patient’s perspective!!! #bcsm

_ShankarSiva's tweet image. Extraordinary case at #SABR2025 by @drspdavid and De Mark Shaw @PeterMacRadOnc oligoprogressive #breastcancer without switching drug therapy. 8 years of SABR with #radonc, with preserved quality of life from the patient’s perspective!!! #bcsm

Steven David reposted

Register now for the next FREE #RSSwebinar on "The Role of Metastasis-Directed Therapy for Oligometastases and Oligoprogression in Breast Cancer" on 10/9 at noon ET featuring @drspdavid, @r_glicksman and @WinstonVuong; moderated by @radicalonc. therss.org/education/webi…

the_RSS's tweet image. Register now for the next FREE #RSSwebinar on "The Role of Metastasis-Directed Therapy for Oligometastases and Oligoprogression in Breast Cancer" on 10/9 at noon ET featuring @drspdavid,  @r_glicksman and @WinstonVuong; moderated by @radicalonc.  therss.org/education/webi…

Congrats to Dr. Belle Sasse on this impactful study! 🎉 Collaboration between @MonashHealth & @PeterMacRadOnc shows metastatic breast MDMs changed treatment plans in 28.1% of patients, highlighting their invaluable role in care. 👉 Read: thebreastonline.com/article/S0960-…

drspdavid's tweet image. Congrats to Dr. Belle Sasse on this impactful study! 🎉 Collaboration between @MonashHealth & @PeterMacRadOnc shows metastatic breast MDMs changed treatment plans in 28.1% of patients, highlighting their invaluable role in care.
👉 Read: thebreastonline.com/article/S0960-…

Steven David reposted

🚩 Sharing our latest article: Here we show that dose dense AC-T, radiotherapy & age affects long-term lymphocyte counts post adjuvant #breastcancer treatment ?implications for IO therapy nature.com/articles/s4152… 👏 @J_DixonDouglas @GustaveRoussy @PeterMacRes @BCRFcure


Steven David reposted

Wonderful summary on #oligometastatic disease and #oligoprogression in #breastcancer by excellent speakers Prue Francis and @drspdavid @BCTrialsANZ #bct2024 Looking forward to AVATAR-2 ⚡️⚡️ @PeterMacRadOnc

janiceyehRO's tweet image. Wonderful summary on #oligometastatic   disease and #oligoprogression in #breastcancer by excellent speakers Prue Francis and @drspdavid 
@BCTrialsANZ #bct2024
Looking forward to AVATAR-2 ⚡️⚡️ @PeterMacRadOnc
janiceyehRO's tweet image. Wonderful summary on #oligometastatic   disease and #oligoprogression in #breastcancer by excellent speakers Prue Francis and @drspdavid 
@BCTrialsANZ #bct2024
Looking forward to AVATAR-2 ⚡️⚡️ @PeterMacRadOnc
janiceyehRO's tweet image. Wonderful summary on #oligometastatic   disease and #oligoprogression in #breastcancer by excellent speakers Prue Francis and @drspdavid 
@BCTrialsANZ #bct2024
Looking forward to AVATAR-2 ⚡️⚡️ @PeterMacRadOnc
janiceyehRO's tweet image. Wonderful summary on #oligometastatic   disease and #oligoprogression in #breastcancer by excellent speakers Prue Francis and @drspdavid 
@BCTrialsANZ #bct2024
Looking forward to AVATAR-2 ⚡️⚡️ @PeterMacRadOnc

Steven David reposted

Our phenomenal #radonc team!! A superbly productive and energising day of aspirations and strategic planning @PeterMacRadOnc #thefutureisbright 😎 @PeterMacCC @svporceddu

PeterMacRadOnc's tweet image. Our phenomenal #radonc team!!

A superbly productive and energising day of aspirations and strategic planning @PeterMacRadOnc

#thefutureisbright 😎

@PeterMacCC @svporceddu

Steven David reposted

Big thank you to @TROGfightcancer and my supportive supervisor @drspdavid @PeterMacRadOnc for a fantastic opportunity to speak at this year’s ASM #TROG2024 #TROGASM24

The breast plenary session at #TROGASM24 continues as Emma Connolly took the stage with the latest update on the groundbreaking Stereotactic Radiotherapy for Oligoprogressive ER-positive Breast Cancer (AVATAR): A Phase II Prospective Multicentre Trial!

TROGfightcancer's tweet image. The breast plenary session at #TROGASM24 continues as Emma Connolly took the stage with the latest update on the groundbreaking Stereotactic Radiotherapy for Oligoprogressive ER-positive Breast Cancer (AVATAR): A Phase II Prospective Multicentre Trial!
TROGfightcancer's tweet image. The breast plenary session at #TROGASM24 continues as Emma Connolly took the stage with the latest update on the groundbreaking Stereotactic Radiotherapy for Oligoprogressive ER-positive Breast Cancer (AVATAR): A Phase II Prospective Multicentre Trial!


Steven David reposted

The breast plenary session at #TROGASM24 continues as Emma Connolly took the stage with the latest update on the groundbreaking Stereotactic Radiotherapy for Oligoprogressive ER-positive Breast Cancer (AVATAR): A Phase II Prospective Multicentre Trial!

TROGfightcancer's tweet image. The breast plenary session at #TROGASM24 continues as Emma Connolly took the stage with the latest update on the groundbreaking Stereotactic Radiotherapy for Oligoprogressive ER-positive Breast Cancer (AVATAR): A Phase II Prospective Multicentre Trial!
TROGfightcancer's tweet image. The breast plenary session at #TROGASM24 continues as Emma Connolly took the stage with the latest update on the groundbreaking Stereotactic Radiotherapy for Oligoprogressive ER-positive Breast Cancer (AVATAR): A Phase II Prospective Multicentre Trial!

Steven David reposted

@piet_ost argues the case for SABR in oligometastatic #prostatecancer - a low toxicity intervention. To better select for patients who benefit most, think biomarkers of the future (genomics), and a role for SABR in mCRPC from ARTO trial #pcsm #radonc #SABR2023

_ShankarSiva's tweet image. @piet_ost argues the case for SABR in oligometastatic #prostatecancer  - a low toxicity intervention. To better select for patients who benefit most, think biomarkers of the future (genomics), and a role for SABR in mCRPC from ARTO trial #pcsm #radonc #SABR2023
_ShankarSiva's tweet image. @piet_ost argues the case for SABR in oligometastatic #prostatecancer  - a low toxicity intervention. To better select for patients who benefit most, think biomarkers of the future (genomics), and a role for SABR in mCRPC from ARTO trial #pcsm #radonc #SABR2023
_ShankarSiva's tweet image. @piet_ost argues the case for SABR in oligometastatic #prostatecancer  - a low toxicity intervention. To better select for patients who benefit most, think biomarkers of the future (genomics), and a role for SABR in mCRPC from ARTO trial #pcsm #radonc #SABR2023
_ShankarSiva's tweet image. @piet_ost argues the case for SABR in oligometastatic #prostatecancer  - a low toxicity intervention. To better select for patients who benefit most, think biomarkers of the future (genomics), and a role for SABR in mCRPC from ARTO trial #pcsm #radonc #SABR2023

Steven David reposted

Off and running at this year’s #SABR2023@PeterMacCC⁩ ⁦@PeterMacRadOnc⁩. Sold out symposium.

svporceddu's tweet image. Off and running at this year’s #SABR2023 ⁦@PeterMacCC⁩ ⁦@PeterMacRadOnc⁩. Sold out symposium.

Steven David reposted

Metastatic #breastcancer at #COSA23 . A/Prof Steven David takes the stage to discuss future directions in #oligometastatic breast cancer care. Alongside A/Prof Shom Goel & Dr Stephen Luen (also from @PeterMacCC) & Kerry Patford, breast care nurse. 👏 @drspdavid @COSAoncology

PeterMacRadOnc's tweet image. Metastatic #breastcancer at #COSA23 . A/Prof Steven David takes the stage to discuss future directions in #oligometastatic breast cancer care. Alongside A/Prof Shom Goel & Dr Stephen Luen (also from @PeterMacCC)  & Kerry Patford, breast care nurse. 👏  @drspdavid @COSAoncology

Steven David reposted

A/Prof Steven David sharing a phase 2 trial of stereotactic #radiotherapy for oligoprogressive ER positive breast #cancer #RANZCR2023

RANZCRcollege's tweet image. A/Prof Steven David sharing a phase 2 trial of stereotactic #radiotherapy for oligoprogressive ER positive breast #cancer #RANZCR2023

Steven David reposted

#AVATAR was a standout at ASTRO this year. Kudos for the remarkable effort!


The COSA AM is in Melbourne this November. It's a highlight of the Australian oncology calendar, and I'm looking forward to presenting on oligometastatic breast cancer. Registrations are at bit.ly/3Mwpunk Hoping to see you there! #COSA23

drspdavid's tweet image. The COSA AM is in Melbourne this November. It's  a highlight of the Australian oncology calendar, and I'm looking forward to presenting on oligometastatic breast cancer.
Registrations are at bit.ly/3Mwpunk
Hoping to see you there! #COSA23

Thanks to the patients and the trial team. AVATAR presented at #ASTRO2023 #radonc @PeterMacRadOnc

drspdavid's tweet image. Thanks to the patients and the trial team. AVATAR presented at #ASTRO2023 #radonc @PeterMacRadOnc

Steven David reposted

Congratulations @drspdavid 👏👏😊 huge amount of work, presented so clearly and with beautiful slides ☺️ @PeterMacRadOnc @PeterMacRes @TROGfightcancer #breastcancer team #ASTRO2023

janiceyehRO's tweet image. Congratulations @drspdavid 👏👏😊 huge amount of work, presented so clearly and with beautiful slides ☺️ @PeterMacRadOnc @PeterMacRes @TROGfightcancer #breastcancer team #ASTRO2023
janiceyehRO's tweet image. Congratulations @drspdavid 👏👏😊 huge amount of work, presented so clearly and with beautiful slides ☺️ @PeterMacRadOnc @PeterMacRes @TROGfightcancer #breastcancer team #ASTRO2023

@drspdavid -late breaking abstract #ASTRO23 - investigating SANR for patients with oligoprogression in ER+ve Her2 -ve #breastcancer. Primary EFS endpoint met, and 1 in 3 patients amenable to repeat SABR, resulting in ‘real world’ mPFS of 10.1mo. 👏🏽👏🏽👏🏽🍾 congrats!!!

_ShankarSiva's tweet image. @drspdavid -late breaking abstract #ASTRO23 - investigating SANR for patients with oligoprogression in ER+ve Her2 -ve #breastcancer. Primary EFS endpoint met, and 1 in 3 patients amenable to repeat SABR, resulting in ‘real world’ mPFS of 10.1mo. 👏🏽👏🏽👏🏽🍾 congrats!!!
_ShankarSiva's tweet image. @drspdavid -late breaking abstract #ASTRO23 - investigating SANR for patients with oligoprogression in ER+ve Her2 -ve #breastcancer. Primary EFS endpoint met, and 1 in 3 patients amenable to repeat SABR, resulting in ‘real world’ mPFS of 10.1mo. 👏🏽👏🏽👏🏽🍾 congrats!!!
_ShankarSiva's tweet image. @drspdavid -late breaking abstract #ASTRO23 - investigating SANR for patients with oligoprogression in ER+ve Her2 -ve #breastcancer. Primary EFS endpoint met, and 1 in 3 patients amenable to repeat SABR, resulting in ‘real world’ mPFS of 10.1mo. 👏🏽👏🏽👏🏽🍾 congrats!!!
_ShankarSiva's tweet image. @drspdavid -late breaking abstract #ASTRO23 - investigating SANR for patients with oligoprogression in ER+ve Her2 -ve #breastcancer. Primary EFS endpoint met, and 1 in 3 patients amenable to repeat SABR, resulting in ‘real world’ mPFS of 10.1mo. 👏🏽👏🏽👏🏽🍾 congrats!!!


Steven David reposted

@drspdavid -late breaking abstract #ASTRO23 - investigating SANR for patients with oligoprogression in ER+ve Her2 -ve #breastcancer. Primary EFS endpoint met, and 1 in 3 patients amenable to repeat SABR, resulting in ‘real world’ mPFS of 10.1mo. 👏🏽👏🏽👏🏽🍾 congrats!!!

_ShankarSiva's tweet image. @drspdavid -late breaking abstract #ASTRO23 - investigating SANR for patients with oligoprogression in ER+ve Her2 -ve #breastcancer. Primary EFS endpoint met, and 1 in 3 patients amenable to repeat SABR, resulting in ‘real world’ mPFS of 10.1mo. 👏🏽👏🏽👏🏽🍾 congrats!!!
_ShankarSiva's tweet image. @drspdavid -late breaking abstract #ASTRO23 - investigating SANR for patients with oligoprogression in ER+ve Her2 -ve #breastcancer. Primary EFS endpoint met, and 1 in 3 patients amenable to repeat SABR, resulting in ‘real world’ mPFS of 10.1mo. 👏🏽👏🏽👏🏽🍾 congrats!!!
_ShankarSiva's tweet image. @drspdavid -late breaking abstract #ASTRO23 - investigating SANR for patients with oligoprogression in ER+ve Her2 -ve #breastcancer. Primary EFS endpoint met, and 1 in 3 patients amenable to repeat SABR, resulting in ‘real world’ mPFS of 10.1mo. 👏🏽👏🏽👏🏽🍾 congrats!!!
_ShankarSiva's tweet image. @drspdavid -late breaking abstract #ASTRO23 - investigating SANR for patients with oligoprogression in ER+ve Her2 -ve #breastcancer. Primary EFS endpoint met, and 1 in 3 patients amenable to repeat SABR, resulting in ‘real world’ mPFS of 10.1mo. 👏🏽👏🏽👏🏽🍾 congrats!!!

Loading...

Something went wrong.


Something went wrong.